OPRX on Nasdaq

OptimizeRx Corp

American business services company, incorporated in Nevada.

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with CASS INFORMATION SYSTEMS INC, Bridger Aerospace Group Holdings, Inc. or FiscalNote Holdings, Inc., or pick any stock.

  • TickerOPRX on Nasdaq
  • IndustryServices-Business Services, NEC
  • HeadquartersNV
  • Incorporated inNV2
  • Business address260 Charles Street, Suite 302, Waltham, Ma 024532
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

67.3%Gross margin3
10.7%Operating margin3
4.7%Net margin3
18.8%Revenue growth, 20253
4.0%Return on equity3
0.17×Debt to equity3
$18.7MFree cash flow3

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Life Science Companies brought in 100% of the revenue OptimizeRx Corp broke down this way in fiscal 2025.

  1. Life Science Companies$109.2M3100%up 28% from 2024
  2. Other Revenue$215.0K30%down 97% from 2024
Products and services by year
Products and services20242025
Life Science Companies$85.5M$109.2M
Other Revenue$6.7M$215.0K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue33¢$35.8M
  • Other costs61¢$66.6M
  • Income tax2¢$1.8M
  • Profit5¢$5.1M

Out of $109.4M in revenue.3

Where each dollar of operating cash went, fiscal 2025

  • Capital spending0¢$58.0K
  • Kept or used elsewhere100¢$18.7M

Out of $18.7M of cash from operations.3

Financial statements

Revenue45673$109.4M in 2025+345% since 2019
0$50.0M$100.0M$150.0M2019: $24.6M$24.6M20192020: $43.3M$43.3M2020+76%2021: $4.5M$4.5M2021−90%2022: $1.0M$1.0M2022−77%2023: $71.5M$71.5M2023+6878%2024: $92.1M$92.1M2024+29%2025: $109.4M$109.4M2025+19%
Gross profit456873$73.6M in 2025+377% since 2019
0$20.0M$40.0M$60.0M$80.0M2019: $15.4M$15.4M20192020: $24.1M$24.1M2020+56%2021: $35.6M$35.6M2021+48%2022: $39.0M$39.0M2022+9%2023: $42.9M$42.9M2023+10%2024: $59.4M$59.4M2024+38%2025: $73.6M$73.6M2025+24%
Operating income456873$11.7M in 2025
-$30.0M-$20.0M-$10.0M0$10.0M$20.0M2019: -$3.7M-$3.7M20192020: -$2.1M-$2.1M2020−42%2021: $361.1K$361.1K20212022: -$12.3M-$12.3M20222023: -$26.4M-$26.4M2023+115%2024: -$13.7M-$13.7M2024−48%2025: $11.7M$11.7M2025
Net income456873$5.1M in 2025
-$30.0M-$20.0M-$10.0M0$10.0M2019: -$3.1M-$3.1M20192020: -$2.2M-$2.2M2020−30%2021: $378.1K$378.1K20212022: -$11.4M-$11.4M20222023: -$17.6M-$17.6M2023+54%2024: -$20.1M-$20.1M2024+14%2025: $5.1M$5.1M2025

Every line of the income statement as filed: the last 2 fiscal years, latest first.3

Period ending2025-12-312024-12-31
Net revenue$109.4M$92.1M
Cost of revenues, exclusive of depreciation and amortization presented separately below$35.8M$32.7M
Gross profit$73.6M$59.4M
Stock-based compensation$7.0M$11.5M
Impairment charges$368.0K$7.5M
Depreciation and amortization$4.3M$4.3M
Other general and administrative expenses$50.2M$49.8M
Total operating expenses$61.9M$73.1M
Income (loss) from operations$11.7M-$13.7M
Interest expense-$5.3M-$6.2M
Other income$198.0K$152.0K
Interest income$353.0K$329.0K
Total other expenses, net-$4.7M-$5.7M
Income (loss) before provision for income taxes$7.0M-$19.4M
Income tax expense-$1.8M-$725.0K
Net income (loss)$5.1M-$20.1M
Weighted average number of shares outstanding basic (in shares)18.6M shares18.3M shares
Weighted average number of shares outstanding diluted (in shares)19.0M shares18.3M shares
Income (loss) per share basic (in dollars per share)$0.28-$1.10
Income (loss) per share diluted (in dollars per share)$0.27-$1.10

Compare OptimizeRx Corp with another company

Leadership

Who has led OptimizeRx Corp, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. David Lester2009–2011
  2. David Harrell2011–2015
  3. William J. Febbo2016–2025
  4. Stephen L. Silvestro2025–now

Chair

  1. David Harrell2009–2010
  2. David Lester2010

President

  1. David Harrell2011
  2. David Lester2011
  3. Miriam J. Paramore2017–2021

Chief financial officer

  1. Douglas P. Baker2014–2021
  2. Edward Stelmakh2021–now

Chief operating officer

  1. David Lester2014
  2. Edward Stelmakh2021–2025
  3. Brendan W. Merrell2025–now
2010201520202025
Board members and other officers (27)

Timeline

  1. Aug 25, 2025New chief executive Stephen L. Silvestro becomes CEO11
  2. Feb 25, 2016New chief executive William J. Febbo becomes CEO12
  3. Jun 1, 2011New chief executive David Harrell becomes CEO13
  4. Jun 22, 2009New chief executive David Lester becomes CEO14

Filings

338 filings to the SEC since October 2021: 6 annual reports, 18 quarterly reports, 50 major events, 209 insider forms, 33 large holders, 22 other. The latest 20:

  1. Oct 2, 20264 EDGAR
  2. Sep 2, 20264 EDGAR
  3. Aug 24, 20264 EDGAR
  4. Aug 24, 20264 EDGAR
  5. Aug 24, 20264 EDGAR
  6. Aug 24, 20264 EDGAR
  7. Aug 24, 20264 EDGAR
  8. Aug 24, 20264 EDGAR
  9. Aug 24, 20264 EDGAR
  10. Aug 24, 20264 EDGAR
  11. Aug 24, 20264 EDGAR
  12. Aug 20, 2026S-8 REGISTRATION STATEMENT EDGAR
  13. Aug 14, 2026SCHEDULE 13G EDGAR
  14. Aug 13, 202610-Q EDGAR
  15. Aug 12, 20268-K EDGAR
  16. Jul 29, 2026SCHEDULE 13G/A EDGAR
  17. Jul 22, 2026SCHEDULE 13G EDGAR
  18. Jun 12, 20268-K CURRENT REPORT EDGAR
  19. Jun 10, 20264 EDGAR
  20. Jun 10, 20264 EDGAR

The 338 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 33 such filings since October 2021, the latest 10:

  1. Aug 14, 2026SCHEDULE 13G
  2. Jul 29, 2026SCHEDULE 13G/A
  3. Jul 22, 2026SCHEDULE 13G
  4. Mar 27, 2026SCHEDULE 13G/A
  5. Oct 31, 2025SCHEDULE 13G
  6. Jul 16, 2025SCHEDULE 13G/A
  7. Apr 30, 2025SCHEDULE 13G/A
  8. Apr 21, 2025SCHEDULE 13D/A
  9. Mar 10, 2025SCHEDULE 13D/A
  10. Feb 13, 2025SCHEDULE 13G/A

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Whetstone Capital Advisors, LLC1,508,303$8.6M2.3%No change
Royce & Associates LP1,089,398$6.2M0.1%+201,368
Vanguard Capital Management LLC699,604$4.0M0.0%+14,155
Kennedy Capital Management LLC644,150$3.7M0.1%−12,108
Rice Hall James & Associates, LLC633,842$3.6M0.2%+31,921
Blair William & Co/il607,925$3.5M0.0%−7,067
Aqr Capital Management LLC583,956$3.3M0.0%+369,002
Dimensional Fund Advisors LP477,687$2.7M0.0%−85,883
BlackRock, Inc.445,382$2.5M0.0%−718,119
Parkman Healthcare Partners LLC350,347$2.0M0.2%−379,022
AWM Investment Company, Inc.240,421$1.4M0.1%+10,000
Geode Capital Management, LLC207,345$1.2M0.0%−184,784
Vanguard Portfolio Management LLC169,538$969.8K0.0%−161,499
Renaissance Technologies LLC167,700$959.2K0.0%−49,156
Marshall Wace, Llp162,186$927.7K0.0%+130,900
P.a.w. Capital Corp160,000$915.2K0.7%+70,000
Citadel Advisors LLC157,992$903.7K0.0%New
Morgan Stanley156,314$894.1K0.0%+79,946
Mink Brook Asset Management LLC141,235$807.9K0.4%New
D. E. Shaw & Co., Inc.138,084$789.8K0.0%−4,839
Jane Street Group, LLC122,086$698.3K0.0%New
Goldman Sachs Group Inc105,037$600.8K0.0%−253,406
Quantinno Capital Management LP99,124$567.0K0.0%+50,102
Vanguard Fiduciary Trust Co97,999$560.6K0.0%−13,130
Trexquant Investment LP89,666$512.9K0.0%−47,208

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45